Hepatic Dysfunction and Jaundice in Patients Receiving Triacetyloleandomycin
- 8 November 1962
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 267 (19) , 964-968
- https://doi.org/10.1056/nejm196211082671905
Abstract
TRIACETYLOLEANDOMYCIN (TriA), a drug that has been introduced for the treatment of infection caused by staphylococcic and other gram-positive organisms, has been widely used, minimal toxicity being reported. Several isolated cases of jaundice in children receiving the drug have been observed.1 , 2 Robinson,3 however, has recently reported that in 5 of 48 patients who received TriA for fourteen days or longer elevated serum glutamic pyruvic transaminase values developed. These observations seem at variance with the previous reports4 , 5 of lack of side effects in patients receiving the drug for periods of sixty days or more.The present study was undertaken in the . . .Keywords
This publication has 11 references indexed in Scilit:
- Antibiotics and Pustulocystic AcneArchives of Dermatology, 1961
- DRUG-INDUCED HEPATIC INJURYAnnals of Internal Medicine, 1959
- Liver cell necrosis in chlorpromazine jaundice (allergic cholangiolitis): A serial study of twenty-six needle biopsy specimens in nine patientsThe American Journal of Medicine, 1959
- Oleandomycin, a laboratory and clinical evaluationThe Journal of Pediatrics, 1958
- Allergy to chlorpromazine manifested by jaundiceThe American Journal of Medicine, 1957
- Serum Glutamic Pyruvic Transaminase in Cardiac and Hepatic Disease.Experimental Biology and Medicine, 1956
- TRANSAMINASE ACTIVITY IN HUMAN BLOODJournal of Clinical Investigation, 1955
- Photosensitivity as a Cause of Falsely Positive Cephalincholesterol Flocculation TestsScience, 1944
- THE DETERMINATION OF BILIRUBIN WITH THE PHOTOELECTRIC COLORIMETERJournal of Biological Chemistry, 1937
- CLINICAL APPLICATION OF THE BROMSULPHALEIN TEST FOR HEPATIC FUNCTIONJAMA, 1925